text: Our results suggest that both drugs were well tolerated in patients with AML or MDS who received chemotherapy and that the efficacy of itraconazole for prophylaxis against systemic fungal disease is not inferior to that of fluconazole .
entities.text: itraconazole
entities.type: intervention
entities.text: fluconazole
entities.type: intervention
entities.text: efficacy
entities.type: outcome
entities.text: patients with AML or MDS who received chemotherapy
entities.type: participant